^
BIOMARKER:

PD-L1 expression

i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Entrez ID:
Related biomarkers:
PD-L1 expression
NSCLC
atezolizumab
Sensitive: A1 - Approval
FDA - 1 week
PD-L1 expression
Cervical Cancer
pembrolizumab + bevacizumab
Sensitive: A1 - Approval
FDA - 1 week
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
pembrolizumab
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
durvalumab
Sensitive: A1 - Approval
PD-L1 expression
SCCHN
pembrolizumab
Sensitive: A1 - Approval
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
PD-L1 expression
RCC
avelumab + axitinib
Sensitive: A1 - Approval
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
PD-L1 expression
Cervical Cancer
pembrolizumab
Sensitive: A1 - Approval
PD-L1 expression
Urothelial Cancer
pembrolizumab
Sensitive: A1 - Approval
PD-L1 expression
SCCHN
pembrolizumab
Sensitive: A1 - Approval
PD-L1 expression
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
PD-L1 expression
Oral Cancer
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Oropharyngeal Cancer
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 expression
SCCHN
ADX-2191
Sensitive: A2 - Guideline
PD-L1 expression
SCCHN
cetuximab
Sensitive: A2 - Guideline
PD-L1 expression
SCCHN
5-fluorouracil
Sensitive: A2 - Guideline
PD-L1 expression
Gastric Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Bladder Cancer
atezolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Bladder Cancer
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Esophageal Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Head and Neck Cancer
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
PD-L1 expression
NSCLC
bevacizumab + atezolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Vulvar Cancer
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 expression
Gastric Adenocarcinoma
nivolumab
Sensitive: A2 - Guideline
PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A2 - Guideline
PD-L1 expression
Triple Negative Breast Cancer
Immunotherapy
Sensitive: A2 - Guideline
PD-L1 expression
NSCLC
nivolumab
Sensitive: B - Late Trials
PD-L1 expression
Clear Cell Renal Cell Carcinoma
pembrolizumab + axitinib
Sensitive: B - Late Trials
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: B - Late Trials
PD-L1 expression
Small Cell Lung Cancer
atezolizumab
Sensitive: B - Late Trials
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: B - Late Trials
PD-L1 expression
Melanoma
pembrolizumab
Sensitive: B - Late Trials
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: B - Late Trials
PD-L1 expression
Gastric Cancer
nivolumab
Sensitive: B - Late Trials
PD-L1 expression
Gastric Cancer
pembrolizumab
Sensitive: B - Late Trials
PD-L1 expression
NSCLC
CS1001
Sensitive: B - Late Trials
PD-L1 expression
Gastric Cancer
Immunotherapy
Sensitive: B - Late Trials
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
Immunotherapy
Sensitive: B - Late Trials
PD-L1 expression
Gastric Cancer
sintilimab
Sensitive: B - Late Trials
PD-L1 expression
Ovarian Cancer
bevacizumab + atezolizumab
Resistant: B - Late Trials
PD-L1 expression
Esophageal Adenocarcinoma
nivolumab
Sensitive: B - Late Trials
PD-L1 expression
NSCLC
tislelizumab
Sensitive: B - Late Trials
PD-L1 expression
RCC
nivolumab + cabozantinib tablet
Sensitive: B - Late Trials
PD-L1 expression
Urothelial Cancer
avelumab
Sensitive: B - Late Trials
PD-L1 expression
Urothelial Cancer
durvalumab
Sensitive: B - Late Trials
PD-L1 expression
Urothelial Cancer
nivolumab
Sensitive: B - Late Trials
PD-L1 expression
Melanoma
nivolumab
Sensitive: B - Late Trials
PD-L1 expression
Melanoma
nivolumab + ipilimumab
Sensitive: B - Late Trials
PD-L1 expression
NSCLC
durvalumab + CP-675206
Sensitive: B - Late Trials
PD-L1 expression
RCC
pembrolizumab + axitinib
Sensitive: B - Late Trials
PD-L1 expression
RCC
bevacizumab + atezolizumab
Sensitive: B - Late Trials
PD-L1 expression
RCC
nivolumab + ipilimumab
Sensitive: B - Late Trials
PD-L1 expression
Bladder Cancer
nivolumab
Sensitive: B - Late Trials
PD-L1 expression
Ovarian Cancer
atezolizumab
Sensitive: B - Late Trials
PD-L1 expression
Ovarian Cancer
CPB
Sensitive: B - Late Trials
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive: B - Late Trials
PD-L1 expression
Cutaneous Melanoma
pembrolizumab
Sensitive: B - Late Trials
PD-L1 expression
NSCLC
cemiplimab
Sensitive: B - Late Trials
PD-L1 expression
Esophageal Squamous Cell Carcinoma
tislelizumab
Sensitive: B - Late Trials
PD-L1 expression
NSCLC
nivolumab + bevacizumab
Sensitive: B - Late Trials
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
sintilimab
Sensitive: B - Late Trials
PD-L1 expression
Esophageal Squamous Cell Carcinoma
sintilimab
Sensitive: B - Late Trials
PD-L1 expression
SCCHN
nivolumab + ipilimumab
Sensitive: B - Late Trials
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab + ipilimumab
Sensitive: C1 - Off-label
PD-L1 expression
LUAD
atezolizumab
Sensitive: C1 - Off-label
PD-L1 expression
SCCHN
durvalumab
Sensitive: C1 - Off-label
PD-L1 expression
Gastric Cancer
nivolumab + ipilimumab
Sensitive: C1 - Off-label
PD-L1 expression
Salivary Gland Cancer
pembrolizumab
Sensitive: C1 - Off-label
PD-L1 expression
BCC
pembrolizumab
Sensitive: C1 - Off-label
PD-L1 expression
Anal Carcinoma
pembrolizumab
Sensitive: C1 - Off-label
PD-L1 expression
Prostate Cancer
pembrolizumab
Sensitive: C1 - Off-label
PD-L1 expression
GastroEsophageal Cancer
pembrolizumab
Sensitive: C1 - Off-label
PD-L1 expression
Squamous Cell Skin Cancer
pembrolizumab
Sensitive: C1 - Off-label
PD-L1 expression
Prostate Cancer
durvalumab
Sensitive: C1 - Off-label
PD-L1 expression
Bladder Cancer
durvalumab
Sensitive: C1 - Off-label
PD-L1 expression
Biliary Tract Cancer
pembrolizumab
Sensitive: C1 - Off-label
PD-L1 expression
Ovarian Cancer
pembrolizumab
Sensitive: C1 - Off-label
PD-L1 expression
Solid Tumor
durvalumab
Sensitive: C1 - Off-label
PD-L1 expression
Solid Tumor
pembrolizumab
Sensitive: C1 - Off-label
PD-L1 expression
Kaposi Sarcoma
pembrolizumab
Sensitive: C1 - Off-label
PD-L1 expression
Biliary Tract Cancer
nivolumab + ipilimumab
Sensitive: C1 - Off-label
PD-L1 expression
Triple Negative Breast Cancer
durvalumab
Sensitive: C1 - Off-label
PD-L1 expression
Melanoma
atezolizumab
Sensitive: C1 - Off-label
PD-L1 expression
Melanoma
durvalumab
Sensitive: C1 - Off-label